These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24403130)

  • 1. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.
    Zheng Z; Hanna N; Onukwugha E; Reese ES; Seal B; Mullins CD
    Cancer Med; 2014 Feb; 3(1):124-33. PubMed ID: 24403130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.
    Zheng Z; Onukwugha E; Hanna N; Bikov K; Seal B; Mullins CD
    Adv Ther; 2014 Jul; 31(7):724-34. PubMed ID: 25022528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients.
    Reese ES; Onukwugha E; Hanna N; Seal BS; Mullins CD
    Cancer Med; 2013 Dec; 2(6):907-15. PubMed ID: 24403264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer.
    Bikov KA; Mullins CD; Hung A; Seal B; Onukwugha E; Hanna N
    Oncologist; 2016 Jun; 21(6):676-83. PubMed ID: 27125751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare.
    Bikov KA; Mullins CD; Seal B; Onukwugha E; Hanna N
    Med Care; 2015 Aug; 53(8):e58-64. PubMed ID: 23552436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
    Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients.
    Woldemichael A; Onukwugha E; Seal B; Hanna N; Mullins CD
    J Manag Care Spec Pharm; 2016 Jun; 22(6):628-39. PubMed ID: 27231791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
    Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
    Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.
    Mayer SE; Tan HJ; Peacock Hinton S; Sanoff HK; Stürmer T; Hester LL; Faurot KR; Jonsson Funk M; Lund JL
    Med Care; 2019 Apr; 57(4):286-294. PubMed ID: 30789540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis.
    Jiao X; Hay JW; Sadeghi S; Barzi A
    Am J Clin Oncol; 2020 Jun; 43(6):428-434. PubMed ID: 32187027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI
    Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
    Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
    Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach.
    Lund JL; Webster-Clark MA; Hinton SP; Shmuel S; Stürmer T; Sanoff HK
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1579-1587. PubMed ID: 33015888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
    Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
    J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining black-white differences in receipt of recommended colon cancer treatment.
    Baldwin LM; Dobie SA; Billingsley K; Cai Y; Wright GE; Dominitz JA; Barlow W; Warren JL; Taplin SH
    J Natl Cancer Inst; 2005 Aug; 97(16):1211-20. PubMed ID: 16106026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
    Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
    Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.